{"id":"avacincaptad-pegol-intravitreal-solution","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"conjunctival hemorrhage"},{"rate":"5-10%","effect":"eye pain"},{"rate":"5-10%","effect":"conjunctival hyperemia"}]},"_chembl":{"chemblId":"CHEMBL4297889","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by binding to VEGF and preventing its interaction with its receptor, thereby inhibiting angiogenesis and reducing vascular permeability. This mechanism is thought to be beneficial in treating conditions characterized by excessive angiogenesis, such as age-related macular degeneration.","oneSentence":"Avacincaptad pegol is an anti-vascular endothelial growth factor (VEGF) agent.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:57:36.750Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of neovascular (wet) age-related macular degeneration"}]},"trialDetails":[{"nctId":"NCT06961370","phase":"PHASE1","title":"A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-07-16","conditions":"Geographic Atrophy, Age-related Macular Degeneration","enrollment":132},{"nctId":"NCT06659445","phase":"PHASE2","title":"Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD","status":"RECRUITING","sponsor":"ONL Therapeutics","startDate":"2025-10-28","conditions":"Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD)","enrollment":324},{"nctId":"NCT02686658","phase":"PHASE2, PHASE3","title":"Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"IVERIC bio, Inc.","startDate":"2015-12-15","conditions":"Geographic Atrophy, Dry Age-Related Macular Degeneration","enrollment":286}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Avacincaptad Pegol intravitreal solution","genericName":"Avacincaptad Pegol intravitreal solution","companyName":"ONL Therapeutics","companyId":"onl-therapeutics","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Avacincaptad pegol is an anti-vascular endothelial growth factor (VEGF) agent. Used for Treatment of neovascular (wet) age-related macular degeneration.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}